FIELD: medicine, pharmacy. SUBSTANCE: invention relates to an anti-calcium agent with prolonged effect. Agent comprises as an active component the compound 7,7'-ethylenedioxybenzopyrane-2,2'-dione (diumancal) in the dose 0.02 g as a solid-dispersed system with polyethylene glycol with molecular mass 1 500 Da and this agent has the name "Ancardin-retard". Invention provides the maintenance of diumancal activity for 26 h as compared with 2 h period for the early known agent. EFFECT: enhanced effectiveness of agent. 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICAMENT WITH PROLONGED ANTI-CALCIUM ACTIVITY IN THE FORM OF 1/10% INTRAVENOUS SOLUTION | 2004 |
|
RU2255728C1 |
| METHOD OF PREPARING DIUMANCAL-FORTE TABLETS IN DOSE 0,01 G | 2000 |
|
RU2187303C2 |
| AGENT FOR TREATMENT OF PATIENT WITH HEART ISCHEMIC DISEASE | 1998 |
|
RU2155036C2 |
| DERIVATIVES OF 2-H-1-BENZOPYRANE-2-ONE ELICITING ANTI-CALCIUM ACTIVITY | 2003 |
|
RU2242471C1 |
| ANTICOAGULANT AGENT OF INDIRECT ACTION ON BASIS OF DIUMANCAL | 2018 |
|
RU2671983C9 |
| ANTIARRHYTHMIC DRUG BASED ON HYBRID MOLECULES OF AMLODIPINE WITH (7-METHOXICUMARIN-4-YL)ACETIC ACID | 2018 |
|
RU2678969C1 |
| ANTIARRHYTHMIC MEDICATION BASED ON 4-METHYL-7,7'-ETHYLENEDIOXY-2H-1-DIBENZOPYRAN-2,2'-DIONE | 2010 |
|
RU2427368C1 |
| ANTICOAGULANT AGENT OF INDIRECTLY ACTION BASED ON NEW HYBRID MOLECULE OF WARFARIN WITH ESSENTIAL ACID | 2018 |
|
RU2677647C1 |
| HYBRID COUMARINS WITH INDIRECT ANTICOAGULANT ACTION | 2018 |
|
RU2672062C1 |
| IMMUNOMODULATORY AND ANTIVIRAL AGENT BASED ON (2-((COUMARIN-7-YL)OXY)ETHYL) 3-HYDROXY-20(29)-LUPEN-28-OATE | 2018 |
|
RU2686743C1 |
